CHERUB Leadership

The CHERUB Collaboration is led by a Scientific Steering Committee (SSC) with representatives from key partners including the community of people living with HIV.


The day-to-day management of the CHERUB Collaboration is led by the CHERUB leadership team.

38911.jpeg

Professor and Consultant Physician in HIV Medicine

Sarah has been involved in designing and leading HIV international clinical studies for participants identified in acute HIV infection, and small proof of concept studies in HIV cure.

John Frater.jpg

John Frater - Oxford University

Scientific lead and co-chair of CHERUB

John has been involved in research focusing on quantification of viral reservoirs, sequence analysis by standard and next generation models, immunology (predominantly looking at the role of CTL in remission strategies) and more fundamental research into new approaches to eradication such as nanotechnology. Working in collaboration with NHS Trusts and with the pharmaceutical industry, the aim to push forward the boundaries in this new and exciting field.

Julie Fox.png

HIV Consultant

HIV consultant that runs the HIV clinical trials unit and carries out studies in HIV prevention and HIV therapeutics. A part of the UK CHERUB collaboration investigating approaches to finding a cure for HIV and leads an HIV prevention programme in sub-Saharan Africa.

Ravi Gupta.jpg

Ravindra Gupta - Cambridge University

Professor of Clinical Microbiology

Research in the Gupta lab focuses on host-pathogen and drug-pathogen interactions to inform HIV treatment and curative strategies. His programme of work is informed by clinical work as an infectious diseases physician in London where he has been able to study unique individuals with HIV in order to better understand viral reservoirs and immune control of HIV. Excitingly, he is currently conducting a study in collaboration with Imperial College aiming to demonstrate the world’s second HIV cure by stem cell transplantation.

Lucy Dorrell.jpeg

Lucy Dorrell - Immunocore / Oxford University

Head of Disease Biology, Infectious Diseases, Immunocore; Professor of Immunology, Oxford University

Group leader for studies surrounding two major groups of viruses ; lentiviruses (retroviruses) and rotaviruses. The lentiviruses include HIV-1, HIV-2 and FIV. In all of these viruses, the focus is on virus assembly, how the virus captures its RNA genome within the cell and how it uses cellular machinery to do this

Jonathan Thornhill.jpg

John Thornhill - Barts Health NHS Trust

Consultant Physician in Sexual Health and HIV

Senior Clinical Research Fellow with an interest in the role of HIV tissue reservoirs and immune dysfunction in HIV persistence. Involved in clinical HIV cure intervention studies at the HIV clinical trials centre at St. Marys Hospital

Sabine Kinloch.jpg

Clinical Scientist

Clinical Scientist in Antiretroviral therapy in early HIV-1 infection, HIV-1 functional cure and eradication, Prophylactic HIV-1 vaccine.

Andrew Lever.jpg

Andrew Lever - Cambridge University

Professor of Infectious Diseases

Studying surrounding two major groups of viruses ; lentiviruses (retroviruses) and rotaviruses. The lentiviruses include HIV-1, HIV-2 and FIV. In all of these viruses, the focus is on virus assembly, how the virus captures its RNA genome within the cell and how it uses cellular machinery to do this.

CHERUB logo new_edited.jpg

Hanna Box, Katie Topping - Imperial College London

CHERUB Project Management

Management of the research operations for CHERUB studies at Imperial College London. 

Hanna is currently project managing the RIO trial and has worked with Prof Fidler for a number of years on multi-centre clinical trials in both the UK and overseas such as RIVER, HPTN 071 PopART, Yathu Yathu, eCLEAR, HEATHER and TREATS. She recently received her Master in Public Health from Imperial College London.

Katie is an experienced research coordinator, having supported key HIV studies including SPARTAC, HPTN 071 PopART, RIVER and MDP at Imperial College London, and has recently joined the RIO trial team.